Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$39.17
pos +0.00
+0.00%
Today's Range: 39.03 - 39.80 | MYL Avg Daily Volume: 5,153,600
Last Update: 07/21/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 2.67%
Open: $0.00
Previous Close: $39.49
52 Week Range: $33.60 - $50.40
Oustanding Shares: 535,981,661
Market Cap: 21,165,915,793
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 5 6
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.09 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 39.10
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
39.10 23.20 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.35% -16.41% -23.78%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.20 $1.45 $5.24 $5.73
Number of Analysts 5 5 7 7
High Estimate $1.26 $1.61 $5.32 $6.03
Low Estimate $1.12 $1.30 $5.17 $5.35
Prior Year $1.16 $1.38 $4.89 $5.24
Growth Rate (Year over Year) 3.10% 5.22% 7.10% 9.44%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

updateCantor Initiates Mylan at Neutral

Jun 16, 2017 | 9:26 AM EDT
Cantor Fitzgerald has initiated coverage of Mylan with a "Neutral" rating.
By

Bruce Kamich

 | May 1, 2017 | 12:18 PM EDT
It looks like the stock is trying to rebase again.
RMPIA
By

Jim Cramer

 | Mar 7, 2017 | 2:00 PM EST
Drug companies are the latest targets/beneficiaries.
By

Jim Cramer

 | Feb 28, 2017 | 11:30 AM EST
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
By

Bruce Kamich

 | Feb 7, 2017 | 10:50 AM EST
Prices look set to test key resistance, and this time should see a breakout to the upside.
RMPIA
By

Jim Collins

 | Jan 12, 2017 | 4:00 PM EST
The stock has taken a beating, but users of Afrezza are loyal to the drug.

bearishMylan downgraded at Citi

Jan 5, 2017 | 7:26 AM EST
MYL was downgraded to Neutral, Citigroup said. $44 price target. Valuation call, as estimates are below consensus.
RMPIA
By

Jim Cramer

 | Jan 3, 2017 | 2:09 PM EST
Even among the losers, buys are scarce.
RMPIA
By

Jim Collins

 | Dec 30, 2016 | 4:00 PM EST
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
By

Jim Cramer

 | Dec 16, 2016 | 11:01 AM EST
Mylan's EpiPen is going to start selling a generic version of its EpiPen allergy treatment with more than a 50% discount.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.